Product Description
Mechanisms of Action: ET Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Heart Failure, Acute|Heart Failure, Chronic|Hypertension, Pulmonary|Pulmonary Heart Disease|Neuromyelitis Optica|Heart Failure
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2009-012450-20 | P2 |
Completed |
Hypertension, Pulmonary |
2011-05-10 |
2022-03-13 |
Treatments |
|
| AC-051-207 | P2 |
Terminated |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2010-12-01 |
2019-03-19 |
Treatments |
|
| AC-051-206 | P2 |
Terminated |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2010-11-01 |
2019-03-19 |
Treatments |
|
| 2006-002907-15 | P3 |
Completed |
Hypertension, Pulmonary|Heart Failure|Pulmonary Heart Disease|Neuromyelitis Optica |
2008-02-08 |
2022-03-12 |
Treatments |
|
| AC-051-350 | P3 |
Terminated |
Pulmonary Heart Disease|Hypertension, Pulmonary |
2008-02-01 |
2019-03-21 |
||
| VERITAS 1 | P3 |
Completed |
Heart Failure, Acute|Heart Failure, Chronic |
2005-01-01 |
2019-03-21 |
||
| VERITAS 2 | P3 |
Completed |
Heart Failure, Acute|Heart Failure, Chronic |
2005-01-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/11/2023 |
PubMed |
Repurposing of the Drug Tezosentan for Cancer Therapy. |
|
09/23/2022 |
PubMed |
Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis. |
|
10/02/2020 |
PubMed |
Endothelin receptor antagonist improves donor lung function in an ex vivo perfusion system. |